FRS fares well in second ad review
This article was originally published in The Tan Sheet
Executive Summary
The Electronic Retailing Self-Regulation Program approves all but one of the claims FRS Co. makes for its FRS Health Energy drinks. ERSP recommended and the Culver City, Calif., firm agreed claims that the ingredient quercetin supports "the immune system like no other antioxidant" and is "clinically proven to boost energy" should be changed to avoid implying no other antioxidant boosts energy. In a March 16 report following a review prompted by an anonymous complaint, ERSP said FRS' evidence supported claims that its products boost energy, increase focus and that its version of quercetin is "the purest" available. In a previous review, the Council of Better Business Bureaus' National Advertising Division said FRS Healthy Energy ads featuring Lance Armstrong must clarify he is endorsing the product as a celebrity, not as a professional cyclist (1"The Tan Sheet" Sept. 22, 2008). Like the ERSP review, NAD agreed the firm supported its claims. In its statement, FRS said it "supports industry's efforts to ensure integrity in the marketplace.
You may also be interested in...
Celebrity Vs. Expert Endorsement Subject Of NAD Review
Future ads for FRS Healthy Energy drinks that feature Lance Armstrong must clarify that the athlete is endorsing the product as a celebrity, not as a professional cyclist, according to the National Advertising Division
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.